HighMark Wealth Management LLC Has $44,000 Stock Holdings in Insmed, Inc. $INSM

HighMark Wealth Management LLC lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 95.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 250 shares of the biopharmaceutical company’s stock after selling 5,500 shares during the quarter. HighMark Wealth Management LLC’s holdings in Insmed were worth $44,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in INSM. EverSource Wealth Advisors LLC lifted its position in shares of Insmed by 65.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 263 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after purchasing an additional 21,176 shares during the last quarter. Baird Financial Group Inc. acquired a new position in shares of Insmed during the 2nd quarter worth about $2,589,000. Amundi lifted its position in shares of Insmed by 21,194.4% during the 2nd quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 11,445 shares during the last quarter. Finally, Natixis acquired a new position in shares of Insmed during the 2nd quarter worth about $1,072,000.

Insider Activity

In other news, insider Michael Alexander Smith sold 19,638 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the sale, the insider directly owned 51,871 shares in the company, valued at approximately $7,831,483.58. This represents a 27.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the sale, the chief executive officer owned 301,185 shares in the company, valued at approximately $43,361,604.45. This represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 161,193 shares of company stock worth $25,462,012. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research analyst reports. Guggenheim cut their price objective on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Royal Bank Of Canada lowered their price target on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research note on Friday, May 8th. Truist Financial set a $185.00 price target on Insmed in a research note on Wednesday. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $166.00 to $212.00 in a research note on Monday, March 30th. Finally, Roth Mkm restated a “buy” rating and set a $212.00 price target on shares of Insmed in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $210.95.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported first-quarter 2026 revenue of $306.0 million, driven by BRINSUPRI sales of $207.9 million and ARIKAYCE revenue of $98.1 million. BRINSUPRI revenue jumped 44% sequentially from Q4 2025, reinforcing confidence that the new product launch is gaining traction. Article Title
• Positive Sentiment: The stock also got support from bargain-hunting after falling to a 10-month low earlier in the week, which helped fuel a sharp rebound in the share price. Article Title
• Neutral Sentiment: At the Bank of America Global Healthcare Conference, Insmed presented an update, but the transcript did not include a clear new catalyst in the headline information provided. Article Title
• Negative Sentiment: HC Wainwright trimmed several future EPS estimates for Insmed, including FY2027, FY2028, FY2029, FY2030, and Q4 2026, which may temper enthusiasm about the pace of longer-term profitability even though the firm kept a Buy rating. MarketBeat coverage

Insmed Trading Up 1.7%

Shares of INSM opened at $117.99 on Thursday. Insmed, Inc. has a 12-month low of $64.85 and a 12-month high of $212.75. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $25.57 billion, a price-to-earnings ratio of -20.52 and a beta of 0.89. The stock’s 50-day moving average price is $142.77 and its 200 day moving average price is $163.95.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same period in the prior year, the company posted ($1.42) EPS. The company’s revenue was up 229.7% compared to the same quarter last year. As a group, research analysts predict that Insmed, Inc. will post -2.56 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.